Stay updated with breaking news from Refractory Multiple. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed... | May 25, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
Faculty from an OncLive® Institutional Perspectives in Cancer webinar on multiple myeloma summarize the main messages from their presentations.
Eight presentations at ASCO and EHA 2023 Annual Meetings showcase continued leadership in CAR-T cell therapy research for patients with multiple myeloma across various clinical settings First... | May 16, 2023
Jeffrey Matous, MD, leads a panel discussion surrounding the use of bispecifics treatment of relapsed / refractory multiple myeloma.